[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaneck Pharmaceutical ETF (PPH)

Vaneck Pharmaceutical ETF (PPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Van Eck Associates
  • Assets Under Management 958,525,400
  • Shares Outstanding, K 9,640
  • 60-Month Beta 0.51
  • Price/Earnings ttm 24.42
  • Annual Dividend & Yield 2.15 (2.17%)
  • Most Recent Dividend 0.844 on 04/01/26
  • Management Fee 0.36%
  • INDUSTRY GROUPING:

    ETFs - Healthcare

Options Overview Details

View History
  • Implied Volatility 23.46% (-0.68%)
  • Historical Volatility 16.34%
  • IV Percentile 88%
  • IV Rank 56.87%
  • IV High 29.78% on 03/30/26
  • IV Low 15.12% on 09/03/25
  • Expected Move (DTE 17) 4.17 (4.18%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 331
  • Open Int (30-Day) 1,061
  • Expected Range 95.59 to 103.92

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.41 +0.14%
on 04/27/26
105.51 -5.65%
on 04/01/26
-1.42 (-1.41%)
since 03/27/26
3-Month
99.41 +0.14%
on 04/27/26
112.58 -11.57%
on 02/17/26
-5.84 (-5.54%)
since 01/28/26
52-Week
81.74 +21.79%
on 08/07/25
112.58 -11.57%
on 02/17/26
+12.10 (+13.84%)
since 04/28/25

Most Recent Stories

More News
What Are Wall Street Analysts' Target Price for Cencora Stock?

Cencora has consistently outperformed the broader market over the past year, and analysts are maintaining a strongly bullish outlook on the company’s growth and earnings potential.

$SPX : 7,120.84 (-0.74%)
COR : 312.37 (+0.71%)
PPH : 99.51 (+0.08%)
Cencora Stock: Is Wall Street Bullish or Bearish?

Pharma distributor Cencora has continued to outpace the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.

$SPX : 7,120.84 (-0.74%)
COR : 312.37 (+0.71%)
PPH : 99.51 (+0.08%)
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease....

NVO : 41.43 (+0.56%)
OZEM : 30.82 (-0.03%)
PPH : 99.51 (+0.08%)
THNR : 24.08 (+0.44%)
Cencora Stock: Analyst Estimates & Ratings

Cencora has outpaced the broader market over the past year, and Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.

$SPX : 7,120.84 (-0.74%)
JPM : 312.72 (+0.35%)
COR : 312.37 (+0.71%)
PPH : 99.51 (+0.08%)
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes drugs....

NVO : 41.43 (+0.56%)
OZEM : 30.82 (-0.03%)
IHE : 85.36 (-0.26%)
LLY : 865.74 (-0.29%)
MEDX : 31.92 (-0.09%)
PPH : 99.51 (+0.08%)
MEDI : 29.49 (+0.36%)
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

Johnson & Johnson JNJ reported stronger-than-expected second-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue...

XLV : 143.71 (+0.17%)
JNJ : 226.82 (+0.66%)
IHE : 85.36 (-0.26%)
IYH : 60.32 (-0.02%)
PPH : 99.51 (+0.08%)
FTXH : 33.49 (-0.44%)
Do Wall Street Analysts Like Cencora Stock?

Cencora has significantly outperformed the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.

$SPX : 7,120.84 (-0.74%)
COR : 312.37 (+0.71%)
PPH : 99.51 (+0.08%)
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises

The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.

VSS : 155.73 (-0.41%)
VXUS : 81.91 (-0.52%)
PPH : 99.51 (+0.08%)
BLCO : 15.73 (-0.94%)
BHC : 5.66 (+1.43%)
Cencora Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Cencora's underperformance relative to the broader market over the past year, Wall Street analysts remain bullish on the stock's future.

$SPX : 7,120.84 (-0.74%)
COR : 312.37 (+0.71%)
PPH : 99.51 (+0.08%)
Is Wall Street Bullish or Bearish on AbbVie Stock?

Despite AbbVie's underperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock's future.

$SPX : 7,120.84 (-0.74%)
PPH : 99.51 (+0.08%)
ABBV : 197.29 (-0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Fund Summary

The VanEck Vectors Pharmaceutical ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical...

See More

Key Turning Points

3rd Resistance Point 101.79
2nd Resistance Point 101.31
1st Resistance Point 100.37
Last Price 99.51
1st Support Level 98.95
2nd Support Level 98.47
3rd Support Level 97.53

See More

52-Week High 112.58
Fibonacci 61.8% 100.80
Last Price 99.51
Fibonacci 50% 97.16
Fibonacci 38.2% 93.52
52-Week Low 81.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.